Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 for advanced gastric cancer that is refractory to S-1 or S-1 plus CDDP: OGSG0701

[1] Koizumi W(2008)S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215-221

[2] Narahara H(2007)Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810-1820

[3] Hara T(1998)Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A) Gan To Kagaku Ryoho Cancer Chemother 25 1915-1924

[4] Sakuramoto S(2007)A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study) Anticancer Res 27 2667-2671

[5] Sasako M(2001)Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions Ann Oncol 12 1133-1137

[6] Yamaguchi T(2002)Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer Gastric Cancer 5 90-95

[7] Taguchi T(2006)Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer Gastric Cancer 9 14-18

[8] Sakata Y(2004)Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model Int J Oncol 25 1531-1536

[9] Kanamaru R(2008)Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts Ann Surg Oncol 15 2301-2309

[10] Kodera Y(2007)Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002) Oncology 73 65-71

[1] Koizumi W(2008)S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215-221

[2] Narahara H(2007)Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810-1820

[3] Hara T(1998)Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A) Gan To Kagaku Ryoho Cancer Chemother 25 1915-1924

[4] Sakuramoto S(2007)A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study) Anticancer Res 27 2667-2671

[5] Sasako M(2001)Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions Ann Oncol 12 1133-1137

[6] Yamaguchi T(2002)Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer Gastric Cancer 5 90-95

[7] Taguchi T(2006)Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer Gastric Cancer 9 14-18

[8] Sakata Y(2004)Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model Int J Oncol 25 1531-1536

[9] Kanamaru R(2008)Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts Ann Surg Oncol 15 2301-2309

[10] Kodera Y(2007)Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002) Oncology 73 65-71